Hagop Kantarjian: Now out in American Journal of Hematology reporting Ph II trial of CLIA +/- Sorafenib in newly diagnosed AML.

Hagop Kantarjian, Department Chair, Department of Leukemia, Division of Cancer Medicine at MD Anderson Cancer Center, shared on Twitter:

“Now out in American Journal of Hematology reporting Ph II trial of CLIA +/- Sorafenib in newly diagnosed AML. With a median F/U of 76 months, CR/CRi Overall was 83% (74% MRD neg) & 4-yr OS of 57%; Among FLT3-ITD, CR/CRi was 95% (81% MRD neg), w/ 5-yr OS of 59%.”

For the article click here.
Source: Hagop Kantarjian/Twitter